Previous 10 | Next 10 |
2023-05-01 10:41:18 ET Cassava Sciences press release ( NASDAQ: SAVA ): Q1 GAAP EPS of -$0.58. At March 31, 2023, cash and cash equivalents were $187.5 million, with no debt. For further details see: Cassava Sciences GAAP EPS of -$0.58
O ver 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam. Completion of patient enrollment for Phase 3 program still expected Q4 2023. $187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE)...
2023-04-28 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-26 13:17:28 ET Summary Patient dosing for the Cognition Maintenance Study of lead candidate simufilam is slated to complete this quarter. CMS top-line results are expected in Q3. New evidence supporting simufilam's mechanism of action (MOA) points to a likely positive ...
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwrigh...
2023-04-26 00:15:28 ET Summary After bringing you the first quarter installment covering large-cap and mid-cap insider activity, today's article will focus on the latest insider activity within the small-cap range. We believe that insiders supply the market with high-quality infor...
2023-04-19 07:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-06 16:43:34 ET Summary Cassava Sciences' Phase 2 open-label safety study of simufilam shows mixed outcomes for treating Alzheimer's disease. Encouraging results offset by study limitations, such as non-randomized design and small sample size. Concerns raised over "rese...
2023-04-06 06:28:02 ET Summary Biogen and Eisa compared the effects of their drug Leqembi against the combined placebo decline rather than against the different rates of decline for APOE4 carriers and non-carriers. This made Leqembi look more effective for non-carriers than it act...
2023-04-05 13:10:09 ET Summary The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. In addition, we will take a look into 2 companies more in-depth, which we found particularly intere...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...